Louisiana House Bill HB263

Louisiana 2020 Regular Session

• Introduced: 2/26/20
• Refer: 2/26/20
• Refer: 3/9/20
• Report Pass: 5/13/20
• Engrossed: 5/22/20
• Refer: 5/25/20
• Report Pass: 5/27/20
• Enrolled: 6/1/20
• Chaptered: 6/11/20
• Passed: 6/11/20

Caption

Provides for insurance coverage of step therapy or fail first protocols

Impact

The bill significantly impacts state laws governing health insurance by establishing a more procedural and evidence-based approach to step therapy practices. Under the new regulations, health coverage plans must outline clear criteria for when overrides can be requested by providers and patients. This includes ensuring a transparent decision-making process and the provision of alternatives if treatment options are denied.

Summary

House Bill 263 introduces important provisions regarding the coverage of step therapy or fail first protocols in health coverage plans in Louisiana. This bill mandates that any health coverage plan utilizing such protocols must comply with specific guidelines to ensure that treatments are based on sound clinical evidence and best practices. The aim is to protect patients from potentially ineffective or harmful treatments, particularly in cases involving severe and chronic health conditions like stage-four cancer.

Sentiment

The sentiment surrounding HB 263 appears to be largely positive among healthcare providers and patients advocating for patient rights and proper healthcare access. The bill is seen as a proactive measure that gives practitioners the tools needed to advocate for their patients effectively. Nevertheless, some concerns were raised about the logistical implications for health coverage plans, particularly in adapting to the new requirements outlined in the bill.

Contention

Notable points of contention include the debate over the adequacy of the proposed guidelines and whether they would be effective in preventing potential harms associated with step therapy protocols. Critics argue that while the intent is to enhance patient care, the implementation process may introduce additional administrative burdens for healthcare providers and insurers, which could inadvertently complicate access to necessary medications.